Does State Medicaid Cover Trulicity (Dulaglutide)?

Dulaglutide, marketed as Trulicity, is a GLP-1 receptor agonist administered by injection once weekly. The FDA has approved Trulicity for two indications in adults with type 2 diabetes: to help control blood sugar levels, and to lower the risk of major cardiovascular events in those with existing heart disease or multiple risk factors for cardiovascular disease. Dulaglutide differs structurally from semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound), which means that Medicaid eligibility and coverage policies may vary between these medications and Trulicity.

Direct answer: For type 2 diabetes, most state Medicaid programs cover Trulicity, almost always behind a prior authorization requirement and usually after documented use of metformin. For obesity as a standalone indication, coverage is inconsistent across states, and many programs do not cover GLP-1 agents for weight management at all. Because Medicaid is state-administered, the only way to know your coverage with confidence is to check your own state's current preferred drug list (PDL) and prior authorization criteria, since these change during annual formulary reviews and sometimes mid-year.

What is established, what is plausible, and what is not established

Established: Medicaid is jointly funded by federal and state governments, but each state sets its own preferred drug list, prior authorization criteria, and step therapy rules under broad federal guardrails (including the 14-day standard PA decision timeline and 72-hour urgent timeline). Dulaglutide's FDA-approved indications are type 2 diabetes glycemic control and cardiovascular risk reduction in T2D, not obesity. Manufacturer copay cards, including the Eli Lilly Savings Card, cannot legally be used by Medicaid beneficiaries under federal anti-kickback rules.

Plausible but state-dependent and not verifiable from a single national source: The specific PA thresholds (HbA1c cutoffs, step therapy sequences, prescriber restrictions, formulary tier), and whether a given state currently covers GLP-1 agents for obesity, vary enough that no general claim about "most states" can substitute for checking that state's current documents.

Not established here: Exact percentages of states covering obesity-related GLP-1 use, exact approval-rate statistics for Medicaid fair hearings, and state-by-state PA criteria as of any specific date. Where the source material for this article did not include a verifiable primary citation for a specific number, that number has been removed or qualified below rather than presented as fact.

T2D versus obesity: two different coverage tracks

Coverage for type 2 diabetes is the more reliable path. Because dulaglutide has FDA approval for T2D glycemic control and cardiovascular risk reduction, and because Medicaid drug rebate agreements reduce net state cost, state Medicaid programs generally include dulaglutide on their formularies for T2D, subject to prior authorization.

Coverage for obesity as a standalone indication is a separate and more restricted track. States have historically had discretion over coverage of weight-loss drugs, and that discretion has translated into wide variation: some state Medicaid programs cover GLP-1 agents for obesity with specific BMI and comorbidity criteria, and others exclude the obesity indication entirely. If you are seeking Trulicity primarily for weight loss without a type 2 diabetes diagnosis, expect a harder coverage path, and confirm your state's current policy before assuming either outcome.

A large cardiovascular outcomes trial in patients with type 2 diabetes and elevated cardiovascular risk (the REWIND trial, published in the Lancet) found that dulaglutide reduced major adverse cardiovascular events compared with placebo over several years of follow-up. This is trial-level evidence specific to the T2D-with-cardiovascular-risk population, not to obesity treatment, and the exact effect size figures should be verified against the original publication before being used in a clinical justification letter, since this article's source material did not include a confirmed link to the primary paper. FDA prescribing and approval information for dulaglutide is available through the FDA's drug database.

How prior authorization typically works

Prior authorization (PA) is the review a state Medicaid plan or its managed care organization performs before approving payment. Common elements across state programs include:

Diagnosis confirmation. An ICD-10 code reflecting type 2 diabetes, generally supported by a recent HbA1c value. Specific HbA1c thresholds differ by state.

Step therapy documentation. Most programs expect documented use of metformin first, and many require a second step (a sulfonylurea, an SGLT-2 inhibitor, or both) before approving a GLP-1 agent, unless there is a documented contraindication or intolerance.

Contraindication screening. Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 are listed contraindications in the FDA label and are commonly asked about on PA forms.

Prescriber and renewal rules. Some states limit initial approval to certain prescriber types or require renewal documentation (continued clinical benefit) at set intervals, though the specific interval and benefit threshold vary by state.

Federal Medicaid regulations set outer bounds on timing: a standard PA decision within 14 calendar days, and an urgent decision within 72 hours when a prescriber certifies that a delay would seriously jeopardize the patient's health. A plan that routinely exceeds these windows can be reported to the state Medicaid agency.

Step therapy in practice

Metformin is almost always the required first step for T2D, typically at a meaningful daily dose for a sustained period (often around 90 days), reflecting both clinical guidelines and metformin's low cost. The second step, when required, is more variable: some states require a sulfonylurea, others accept an SGLT-2 inhibitor, and a minority require both before approving a GLP-1 agent.

Step therapy for an obesity-only indication, in the states that cover it at all, is generally stricter still and commonly includes a period of documented behavioral or lifestyle intervention and, in some programs, a prior trial of a non-GLP-1 weight-loss medication. The American Association of Clinical Endocrinology has published consensus guidance supporting pharmacotherapy as an adjunct to lifestyle intervention in patients with a BMI of 30 or above, or 27 or above with weight-related comorbidities, rather than requiring lifestyle failure as a strict precondition in higher-risk patients. AACE clinical guidance is available through the Endocrine Society. The exact wording of any specific consensus statement should be verified directly before being quoted in an appeal letter.

Formulary tier and cost sharing

Where covered, dulaglutide typically sits on a non-preferred or specialty tier in state Medicaid formularies, which affects prior authorization difficulty more than it affects your actual copay. Federal law caps Medicaid cost sharing at modest levels: nominal amounts (commonly a few dollars or less) for non-preferred drugs, with even lower amounts or no cost sharing for beneficiaries at or below 150% of the federal poverty level. Beneficiaries who are dually eligible for Medicare and Medicaid generally have drug coverage handled through Medicare Part D rather than Medicaid, which changes the coverage analysis entirely for that group.

Tier placement is reviewed on a regular cycle, commonly annually, and can shift if rebate agreements or competing GLP-1 formulary positions change. Checking your state's current preferred drug list directly, rather than relying on a prior year's information, is the single most useful step before filing a PA.

State variation: an important caution

State Medicaid programs differ enough in their obesity coverage policy, step therapy sequence, and formulary tier that no general summary can substitute for the current document from your own state. This article's source material did not include verified, dated citations to individual state PDLs or PA criteria, so specific state-by-state claims are intentionally not made here. If you need a same-day answer, your state Medicaid member services line, or your managed care plan's published PDL and PA criteria, is the authoritative source, and it should be checked as of the current date since formularies change during the year.

Appealing a denial

A denial is not final. The general federal framework works roughly like this:

1. Get the written denial reason. The notice should state whether the denial was for incomplete PA documentation, unmet step therapy, an indication not covered (for example, obesity where the state excludes it), or a formulary exclusion.
2. File an internal grievance with the managed care plan if one is required before a fair hearing, and include any additional clinical documentation that addresses the stated denial reason.
3. Request a state Medicaid fair hearing within 90 days of the denial notice. If you were previously receiving the drug and want coverage to continue during the appeal, most states require you to request continuation of benefits within a much shorter window (commonly around 10 days), so act quickly if this applies.
4. Build a documentation-heavy appeal package: a prescriber clinical justification letter, relevant trial evidence (cardiovascular outcome data for T2D patients at elevated risk, verified against the primary publication), applicable guideline language from bodies such as the American Diabetes Association, and documentation of step therapy completion or a clinical reason it was not appropriate. The American Diabetes Association's Standards of Care collection is available through Diabetes Care.

Published, systematic data on Medicaid fair-hearing approval rates for dulaglutide specifically were not available in the source material for this article. In general Medicaid appeals experience, more complete documentation tends to correlate with better outcomes, but that is a general pattern rather than a dulaglutide-specific statistic, and patients should understand this represents observed trends rather than predictable individual outcomes.

Manufacturer savings cards and patient assistance

The Eli Lilly Savings Card for Trulicity cannot legally be used by Medicaid beneficiaries; this is a federal anti-kickback statute restriction, not a gray area. Options that may be available to Medicaid patients instead include manufacturer patient assistance programs (such as Lilly Cares), which have their own income eligibility rules that should be confirmed directly with the program rather than assumed, and in some states, a state pharmaceutical assistance program that can wrap around Medicaid. Availability of both varies and should be verified at the time of need rather than relied on from a prior year's information.

Decision framework: which coverage path applies to you

Use this to figure out which facts actually change your next step, rather than reading the entire policy landscape.

Exceptions worth flagging to your prescriber: a documented adverse reaction to a required step therapy drug, a contraindication (such as low eGFR for metformin), and a personal or family history of medullary thyroid carcinoma or MEN2, which is a contraindication to dulaglutide itself and should stop a PA request rather than support one.

When to seek urgent care instead of waiting on an appeal

Medicaid coverage delays are an administrative problem, not a medical emergency, but do not wait on an appeal if you experience symptoms of severe hypoglycemia, signs of pancreatitis (severe abdominal pain, persistent vomiting), or signs of an allergic reaction after a dose. Those situations need urgent medical evaluation regardless of coverage status.